Oragenics, Inc. (NYSEAMERICAN:OGEN) Short Interest Down 46.5% in January

Oragenics, Inc. (NYSEAMERICAN:OGEN) was the target of a significant decrease in short interest during the month of January. As of January 15th, there was short interest totaling 57,838 shares, a decrease of 46.5% from the December 31st total of 108,196 shares. Based on an average trading volume of 34,528 shares, the days-to-cover ratio is currently 1.7 days. Currently, 1.5% of the shares of the stock are sold short. Currently, 1.5% of the shares of the stock are sold short. Based on an average trading volume of 34,528 shares, the days-to-cover ratio is currently 1.7 days.

Institutional Investors Weigh In On Oragenics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Bank of America Corp DE raised its position in Oragenics by 7,374.0% during the second quarter. Bank of America Corp DE now owns 15,546 shares of the company’s stock valued at $59,000 after purchasing an additional 15,338 shares during the period. Sabby Management LLC purchased a new position in Oragenics during the third quarter worth $77,000. Finally, Clear Street LLC bought a new position in Oragenics during the second quarter valued at $270,000. Institutional investors own 18.71% of the company’s stock.

Oragenics Price Performance

OGEN traded up $0.02 during midday trading on Friday, reaching $0.84. 59,373 shares of the company’s stock traded hands, compared to its average volume of 913,663. The stock has a market capitalization of $3.59 million, a price-to-earnings ratio of -0.07 and a beta of 0.90. Oragenics has a 52 week low of $0.74 and a 52 week high of $18.90. The firm has a fifty day moving average of $0.87 and a two-hundred day moving average of $1.11.

Oragenics (NYSEAMERICAN:OGEN) last released its earnings results on Friday, November 7th. The company reported ($1.96) earnings per share for the quarter.

Oragenics Company Profile

Oragenics, Inc is a clinical-stage biotechnology company focused on the research and development of novel anti-infective therapeutics targeting oral and mucosal diseases. Headquartered in Tampa, Florida, the company leverages proprietary technologies to address unmet needs in dental and oral healthcare, with an emphasis on innovative treatments that can improve patient outcomes and reduce reliance on traditional antibiotics.

The company’s lead product candidate, Oraprev™, is being developed as a pre-procedural rinse designed to reduce oral microbial load prior to dental procedures.